Moomoo AI 已提取核心訊息
On February 28, 2024, Novavax, Inc. reported its financial results for the fourth quarter and full year of 2023. The company announced Q4 revenues of $291 million and full-year revenues of $1.0 billion. Novavax also provided guidance for 2024, projecting total revenues between $800 million to $1 billion. The company has made significant strides in reducing operating expenses by 41% compared to 2022 and has reduced its workforce by 30% since Q1 2023. Novavax settled with Gavi regarding a 2021 advance purchase agreement, which has removed financial uncertainty. The company is progressing with its Phase 3 COVID-19-Influenza Combination vaccine trial, expected to begin in the second half of 2024, with a potential launch in 2026. Novavax's net loss for Q4 was $178 million, an improvement over the $182 million loss in the same period the previous year. The company ended the year with $584 million in cash and cash equivalents.
On February 28, 2024, Novavax, Inc. reported its financial results for the fourth quarter and full year of 2023. The company announced Q4 revenues of $291 million and full-year revenues of $1.0 billion. Novavax also provided guidance for 2024, projecting total revenues between $800 million to $1 billion. The company has made significant strides in reducing operating expenses by 41% compared to 2022 and has reduced its workforce by 30% since Q1 2023. Novavax settled with Gavi regarding a 2021 advance purchase agreement, which has removed financial uncertainty. The company is progressing with its Phase 3 COVID-19-Influenza Combination vaccine trial, expected to begin in the second half of 2024, with a potential launch in 2026. Novavax's net loss for Q4 was $178 million, an improvement over the $182 million loss in the same period the previous year. The company ended the year with $584 million in cash and cash equivalents.
2024年2月28日，Novavax, Inc.公佈了其2023年第四季度和全年財務業績。該公司宣佈第四季度收入爲2.91億美元，全年收入爲10億美元。Novavax還提供了2024年的指導方針，預計總收入在8億美元至10億美元之間。與2022年相比，該公司在將運營支出減少41％方面取得了長足的進步，並且自2023年第一季度以來裁員了30％。Novavax與Gavi就2021年的預購協議達成和解，該協議消除了財務不確定性。該公司的3期COVID-19流感聯合疫苗試驗正在取得進展，該試驗預計將於2024年下半年開始，並可能在2026年啓動。Novavax第四季度的淨虧損爲1.78億美元，比去年同期的1.82億美元虧損有所改善。該公司在年底擁有5.84億美元的現金和現金等價物。
2024年2月28日，Novavax, Inc.公佈了其2023年第四季度和全年財務業績。該公司宣佈第四季度收入爲2.91億美元，全年收入爲10億美元。Novavax還提供了2024年的指導方針，預計總收入在8億美元至10億美元之間。與2022年相比，該公司在將運營支出減少41％方面取得了長足的進步，並且自2023年第一季度以來裁員了30％。Novavax與Gavi就2021年的預購協議達成和解，該協議消除了財務不確定性。該公司的3期COVID-19流感聯合疫苗試驗正在取得進展，該試驗預計將於2024年下半年開始，並可能在2026年啓動。Novavax第四季度的淨虧損爲1.78億美元，比去年同期的1.82億美元虧損有所改善。該公司在年底擁有5.84億美元的現金和現金等價物。
有用
沒用